Article
Targeting Neuropilin-1 to Enhance Immunotherapy in Melanoma: Reducing Peripheral Treg-Mediated Immunosuppression and Tumour Progression
2024-09-30
Abstract excerpt
Melanoma, the most aggressive type of skin cancer with a high mutation rate, is the fifth most common cancer among Caucasians. Despite advancements in treatments like immune checkpoint inhibitors and targeted therapies, over 40% of patients experience immune-related side effects, presenting significant challenges. Neuropilin-1 (NRP1) has become an essential target in cancer therapy due to its overexpression in var...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 2f735af5-de41-5546-ac9e-539d683f4724
- DOI
- 10.1101/2024.09.27.615359
